Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-733

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-733 Category Tag

Product Details

Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

Products Name (INN Index)

Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A

INN Name

anatumomab mafenatox

Target

tag-72

Format

Fusion Protein

Derivation

Mus musculus

Species Reactivity

Human

CH1 Isotype

Fab – G1 – kappa

VD LC

Fab – G1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

NA

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TAG-72

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide